"uuid:ID","name","id","description","label","rationale","instanceType"
"ee9b3377-0566-4918-ae54-3004aaab4619","Study Design 1","StudyDesign_1","The main design for the study","","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign"
